Barbara Gayle Duncan - Insider Trading & Ownership

Entity
Individual
Location
C/O Intercept Pharmaceuticals, Inc., 18 Desbrosses Street, New York, NY
Summary
The estimated net worth of Barbara Gayle Duncan is at least $964K dollars as of December 16, 2024. Barbara Gayle Duncan is the Director of HALOZYME THERAPEUTICS, INC. and owns shares of HALOZYME THERAPEUTICS, INC. (HALO) stock worth about $728K. Barbara Gayle Duncan is the Director of Atea Pharmaceuticals, Inc. and owns shares of Atea Pharmaceuticals, Inc. (AVIR) stock worth about $236K.
All Insider Reports
All Insider Reports

Ownership of Barbara Gayle Duncan

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
HALO HALOZYME THERAPEUTICS, INC. Director $728K Apr 25, 2024
AVIR Atea Pharmaceuticals, Inc. Director $236K Jun 21, 2024
ADAP Adaptimmune Therapeutics PLC Director Jul 1, 2022
FUSN Fusion Pharmaceuticals Inc. Director Jun 4, 2024
JNCE Jounce Therapeutics, Inc. Director May 3, 2023
OVID Ovid Therapeutics Inc. Director Dec 12, 2024

Insider Transactions Reported by Barbara Gayle Duncan:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.